Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Condition:   Head and Neck Cancer
Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cetuximab/Erbitux;   Drug: Cisplatin/Platinol;   Drug: Carboplatin/Paraplatin;   Drug: Fluorouracil/Adrucil
Sponsor:   Bristol-Myers Squibb
Not yet recruiting - verified April 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/23StOi3
via IFTTT